id: benzodiazepine_use_in_maw_to_adverse_cognitive_outcomes
name: Benzodiazepine Use in Medically Assisted Withdrawal â†’ Adverse Cognitive and
  Safety Outcomes
from_node:
  node_id: benzodiazepine_use_in_maw
  node_name: Benzodiazepine Use in Medically Assisted Withdrawal
to_node:
  node_id: adverse_cognitive_outcomes
  node_name: Adverse Cognitive and Safety Outcomes
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Benzodiazepines are used as standard treatment for alcohol withdrawal despite
  clear evidence base'
- 'Step 2: Benzodiazepines produce multiple adverse effects including blunting of
  cognition, interactions with depressant drugs, and disrupted sleep patterns'
- 'Step 3: Additional risks include abuse liability, craving, delirium, and dementia'
- 'Step 4: These adverse effects create barriers to safe withdrawal completion and
  ongoing treatment engagement'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: E. Day and C. Daly 2021. "Clinical Management of the Alcohol Withdrawal
    Syndrome.." *Addiction*. https://doi.org/10.1111/add.15647
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.715695'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: concurrent_depressant_drug_use
  direction: strengthens
  strength: strong
  description: Benzodiazepines interact with other depressant drugs, increasing risk
    of adverse outcomes
- name: older_age
  direction: strengthens
  strength: strong
  description: Older adults may have increased vulnerability to cognitive blunting,
    delirium, and dementia risks from benzodiazepines
